Jaymes H Collins1, Shannon M Lenz1, Nashone A Ray1, Marivic F Balagon2, Deanna A Hagge3, Ramanuj Lahiri1, Linda B Adams1. 1. United States Department of Health and Human Services, Health Resources and Services Administration, Health Systems Bureau, National Hansen's Disease Program, Baton Rouge, Louisiana. 2. Leonard Wood Memorial, Center for TB and Leprosy Research, Cebu, Philippines. 3. Mycobacterial Research Laboratories, Anandaban Hospital, Kathmandu, Nepal.
Abstract
Mycobacterium leprae, the etiologic agent of leprosy, cannot be cultured on artificial media. This characteristic, coupled with its long generation time, presents a number of unique challenges to studying this pathogen. One of the difficulties facing both researchers and clinicians is the absence of a rapid test to measure the viability of M. leprae in clinical or experimental specimens. The lack of such a tool limits the understanding of M. leprae immunopathogenesis and makes determining the efficacy of drug treatments difficult. With this in mind, we developed a robust two-step molecular viability assay (MVA) that first enumerates the M. leprae in the tissue; then, this data is used to normalize bacterial RNA quantities for the second step, in which the expression of M. leprae esxA and hsp18 are measured. This assay is specific and sensitive enough to be used on most clinical samples. This protocol describes the steps required to extract DNA and RNA from M. leprae-infected tissue, enumerate M. leprae, and measure M. leprae viability based on the normalized expression of two M. leprae-specific genes (hsp18 and esxA). This protocol also outlines an optimal laboratory design and workflow for performing this assay.
Mycobacterium leprae, the etiologic agent of leprosy, cannot be cultured on artificial media. This characteristic, coupled with its long generation time, presents a number of unique challenges to studying this pathogen. One of the difficulties facing both researchers and clinicians is the absence of a rapid test to measure the viability of M. leprae in clinical or experimental specimens. The lack of such a tool limits the understanding of M. leprae immunopathogenesis and makes determining the efficacy of drug treatments difficult. With this in mind, we developed a robust two-step molecular viability assay (MVA) that first enumerates the M. leprae in the tissue; then, this data is used to normalize bacterial RNA quantities for the second step, in which the expression of M. leprae esxA and hsp18 are measured. This assay is specific and sensitive enough to be used on most clinical samples. This protocol describes the steps required to extract DNA and RNA from M. leprae-infected tissue, enumerate M. leprae, and measure M. leprae viability based on the normalized expression of two M. leprae-specific genes (hsp18 and esxA). This protocol also outlines an optimal laboratory design and workflow for performing this assay.
Authors: Rahul Sharma; Pushpendra Singh; Rajiv C McCoy; Shannon M Lenz; Kelly Donovan; Maria T Ochoa; Iris Estrada-Garcia; Mayra Silva-Miranda; Fermin Jurado-Santa Cruz; Marivic F Balagon; Barbara Stryjewska; David M Scollard; Maria T Pena; Ramanuj Lahiri; Diana L Williams; Richard W Truman; Linda B Adams Journal: Clin Infect Dis Date: 2020-11-05 Impact factor: 9.079
Authors: Diana L Williams; Marina Torrero; Paul R Wheeler; Richard W Truman; Mark Yoder; Norman Morrison; William R Bishai; Thomas P Gillis Journal: J Mol Microbiol Biotechnol Date: 2004
Authors: Grace L Davis; Nashone A Ray; Ramanuj Lahiri; Thomas P Gillis; James L Krahenbuhl; Diana L Williams; Linda B Adams Journal: PLoS Negl Trop Dis Date: 2013-08-22
Authors: Richard W Truman; P Kyle Andrews; Naoko Y Robbins; Linda B Adams; James L Krahenbuhl; Thomas P Gillis Journal: PLoS Negl Trop Dis Date: 2008-11-04
Authors: Rubikah Vimonish; Janaina Capelli-Peixoto; Wendell C Johnson; Hala E Hussein; Naomi S Taus; Kelly A Brayton; Ulrike G Munderloh; Susan M Noh; Massaro W Ueti Journal: Front Cell Infect Microbiol Date: 2022-05-31 Impact factor: 6.073